High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900 Meeting Abstract

  

Authors:	Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; Levine, R. L.; Sun, Z. X.; Luger, S. M.
Abstract Title:	High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900
Meeting Title:	56th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	124
Issue:	21
Meeting Dates:	2014 Dec 6-9
Meeting Location:	San Francisco, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2014-12-06
Language:	English
ACCESSION:	WOS:000349243505099
PROVIDER:	wos
DOI:	10.1182/blood.V124.21.373.373
Notes:	Meeting Abstract: 373 -- 56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CA -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/71473